Abstract Background: Ventilator associated pneumonia (VAP) remains an area of active clinical research with little data about effect of (VAP) on outcome among patients with acute exacerbation of chronic obstructive pulmonary disease.
Introduction
Ventilator-associated pneumonia (VAP) is defined as pneumonia occurring more than 48 h after initiation of endotracheal intubation and mechanical ventilation [1] . It is the commonest nosocomial infection in the intensive care unit with an incidence ranging from 8-28% in mechanically ventilated patients and was associated with high morbidity and mortality [2, 3] . VAP is usually classified as early onset when it develops 4 days from intubation and late onset when it develops after 5 days and this distinction is significant when considering etiological agents, seriousness, prognosis and therapeutic implications [4] .
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality [5] . Its natural course is characterized by exacerbations which lead to acute respiratory failure and hospitalization [6] . Although noninvasive mechanical ventilation (NIV) is ''the standard of care'' for management of acute exacerbation of COPD; mechanical ventilation has a role in large number of cases because of clinical condition or no improvement on NIV [7] .
Endotracheal intubation is performed among these patients to save life; however, it may be complicated by VAP. Also COPD is a known risk factor for nosocomial lower respiratory infections [8, 9] . Various factors which may contribute to the increased risk of lower respiratory infections among these patients include presence of structural lung damage, repeated hospitalization, usage of antibiotic, and corticosteroids. Invasive devices and procedures and antimicrobial therapy create favorable media for antimicrobial resistant pathogen to colonize the aerodigestive tract.
Considering the risk factor of these patients, VAP is expected to have significant adverse outcome on the clinical course of COPD patients. VAP is still good field of clinical research with little data about effect of VAP on outcome among patients with acute exacerbation of chronic obstructive pulmonary disease.
Patients and methods
A prospective, single-center, observational, clinical study in medical intensive care unit (MICU) and respiratory intensive care unit over a 12 months period from July 2012 to March 2014. The study was approved from faculty ethics committee. Because it was an observational study, the requirement for written informed consent was waived.
Inclusion criteria
Patients with acute exacerbation of COPD were eligible for the study if placed on mechanical ventilation (MV) for P48 h.
Exclusion criteria
All patients with clinical and radiological signs suggestive of pneumonia or acute respiratory distress syndrome (ARDS) secondary to pneumonia on admission were excluded.
Data collection
For each patient the following data are collected: demographic data, admission diagnosis, co morbid condition, date of MV, date of VAP diagnosis, clinical pulmonary infection score at the day of VAP diagnosis, possible risk factors for VAP; prior use of antibiotics >7 days, re-intubation, diabetes mellitus, recent surgery, oral steroid use >2 weeks. Result of quantitative cultures of endotracheal aspirates in term of identified organism and their antimicrobial resistance patterns, duration of mechanical ventilation, intensive care unit length of stay (ICU LOS) and patient outcome with either discharge from ICU or died.
The eligible patients were carefully followed up for signs of VAP. This included apart from clinical examination, regular recording of body temperature, observance of tracheal aspirate appearance, leukocyte count and chest radiograph.
The diagnosis of VAP was based on the American College of Chest Physicians criteria as an association of a new or progressive consolidation on chest radiology plus at least two of the following variables: fever greater than 38°C, leukocytosis or leukopenia, and purulent secretions (ATS, 2005) [10] .
VAP is classified as follows
Early onset when it develops 3-5 days from intubation; and late onset when it develops after 5 days. Modified clinical pulmonary infection score is calculated at the day of VAP diagnosis [11] . Patients with clinical diagnosis of VAP (based on the above criteria) underwent endotracheal aspirate (ETA). Quantitative culture done for all patients and the threshold for ETA was considered as 10 5 cfu/ml. Growth of any organism below this threshold was assumed to be colonization or contamination.
Statistical analysis
All statistical analyses were performed using SPSS version 14.0 software (Chicago, IL, USA). Categorical variables were analyzed using the c2 test or Fisher's exact test. Continuous variables were compared using Student t test or the MannWhitney U test. Multivariate logistic regression analyses were performed to identify the risk factors. Statistical significance was set to a value of P 6 0.05.
Results
During the study period 152 patients were enrolled and divided into two groups VAP group 92 patients (60%) and without VAP group 60 patients (40%). The mean age was lower in VAP patients and most of them were in middle age (52.3%) and of male gender (63%). ICU length of stay and duration of mechanical ventilation were statistically significantly longer in VAP group, and so CPIS. Mortality was more in VAP patients as shown in Table 1 .
There were 38 patients (41%) developed early VAP while 54 patients (59%) developed late VAP. Late one was associated with longer ICU length of stay, duration of MV, higher CPIS and higher mortality than early VAP and the P value was highly significant as shown in Table 2 .
As regards possible risk factors for early vs. late VAP, prolonged antibiotic use was more in late VAP with significant P value; also re-intubation was recorded more in late VAP patients as shown in Table 3 .
Univariate and multivariate analysis was done for identifying factors affecting occurrence of early vs. late VAP. Prior antibiotics use and ICU intubation were identified by final model of multivariate analysis to be more associated with the occurrence of late VAP (odds ratio <1, and P value <0.05) as shown in Tables 4 and 5 .
Regarding factors predicting death in VAP patients using Univariate and multivariate analysis late VAP, old age and prolonged use of antibiotics were identified by final model as factors predicting death in VAP patients as shown in Tables  6 and 7 .
Discussion
COPD is a known risk factor for VAP occurrence and is related to adverse VAP outcomes [12] . In our study VAP was diagnosed in 60% of patients and this percentage is higher than the range that was reported for VAP in recent review of literature which was 9-40% of intubated heterogeneous patients [13] . Early onset VAP in our study was found to be 41% which is consistent with findings in various studies [14, 15] . Gram negative organisms had been identified in 56% isolates and most of them were Klebsiella spp. followed by Escherichia coli while Gram Positive Cocci were responsible for 44% of the isolates most of them were multi resistant staph aureus. This is in agreement with Arabi et al., and Lagamayo [16, 17] .
Most of the VAP patients were of middle age group while most of non VAP patients were older; more than 60 years. Most patients were males in both groups. This in concordance with Al-Dorzi et al. [18] . Our study confirms the associations of VAP with adverse patients' outcomes as VAP patients have longer duration of MV and ICU LOS than non VAP patients (P value was highly significant <0.0001). These findings are consistent Ertugrul et al., and Kollef et al. [19, 20] .
Mortality was higher in VAP patients than non VAP, nearly 48% of them and this is in agreement with Nseir et al., and Gupta et al. [12, 21] . Those VAP patients who died were significantly older than those who had been discharged (P value 0.03). There was significant difference in gender, ICU LOS and duration of MV (though was shorter in discharge group). CPIS was P6 in all patients who died which raises the question of its value in follow up of VAP patients and prediction of mortality.
Longer ICU LOS, duration of MV and higher mean CPIS were observed in late onset VAP than early VAP and the difference was statistically significant. Same results were reached by Raymond et al. [22] . Mortality was higher in L-VAP (59.26%) than E-VAP (31.58%). The same finding was observed by Varun et al. [15] .
As regards risk factors for VAP we found that prior antibiotic, re-intubation, and DM were recorded at higher percentage in L-VAP than E-VAP. Antibiotic prescription is probably a risk factor for L-VAP in comparison to E-VAP with significant P value 0.001 as antibiotic-resistant bacteria were isolated more often in L-VAP. Some studies have also shown that antibiotic prescription protects against E-VAP [9] . Other investigator found that antibiotic prescription and prior hospitalization enhance the subsequent infection with resistant pathogens [23] .
Final multivariate logistic regression of factors affecting occurrence of E-VAP vs. L-VAP identified prior antibiotic use and ICU intubation to be associated with the occurrence of late VAP. It is consistent with Giard et al. [12] . After adjustment for other factors by multivariate analysis for identifying predictors of mortality in patients with AECOPD with VAP revealed that old age, re-intubation, and prolonged use of antibiotics were more prevalent in death group with significant and highly significant P value (0.02, 0.03 and <0.001 respectively).
There is some explanation for increased mortality in COPD patients with VAP in ICU related to respiratory muscle dysfunction, VAP caused by multidrug resistant organism with high risk of receiving inappropriate initial antibiotic treatment which has been identified as a risk factor for mortality in ICU patients. Cunningham et al., stated that mortality in critically ill COPD might be related to other components of the disease such as cachexia that may affect adversely the immune response [24] .
There is some limitation of our study related to single center study and limited number of cases as regards studying of mortality so more work in this field is needed.
Conclusion
Ventilator associated pneumonia VAP remains a common complication of ventilator support for patients with AECOPD and is associated with high morbidity and mortality. Elderly, late onset VAP, re-intubation and prolonged use of antibiotics were predictors of mortality in VAP patients with AECOPD.
